Bringing a therapy, medical device, diagnostic, or digital health solution to market takes years of investment, planning, and execution. As organizations work to increase speed to market, they are balancing a variety of pressures that can cause delays.
The good news is that many delays stem from operational challenges that can be addressed. Clinical trial startup, manufacturing readiness, tech transfer, and workforce shortages all influence how quickly a product reaches commercialization. Organizations that identify and address these barriers early often create shorter development timelines and stronger product launches.
Why Increasing Speed to Market Matters
One of the strongest reasons to accelerate development and commercialization is the impact on patients. Many therapies address serious or life-threatening conditions where treatment options are limited.
According to the FDA, more than 30 million Americans live with a rare disease, and most rare diseases still lack approved treatments. When development timelines are shortened, patients gain access to potentially life-changing therapies sooner.
Additionally, drug and device development requires substantial investment long before a product reaches the market. Delays can extend operational costs, postpone revenue generation, and create uncertainty around future growth.
Every month spent waiting on trial enrollment, facility readiness, technology transfer, regulatory review, or manufacturing scale-up can impact profitability. Faster commercialization allows organizations to begin recouping R&D investments earlier while increasing the effective market life of products before patent exclusivity expires.
For publicly traded companies, development delays can also affect shareholder confidence and future investment decisions.
Challenges Affecting Speed to Market
In many cases, the underlying issue is not scientific complexity, but rather the work required to transition programs from one phase to the next.
Clinical and Regulatory Process Complexity
The path to commercialization involves far more than clinical research. Development teams must coordinate regulatory filings, quality documentation, manufacturing preparedness, supply chain planning, validation activities, and inspection readiness.
The FDA’s Center for Drug Evaluation and Research reported reviewing thousands of investigational new drug applications and clinical trial protocols annually, illustrating the scale of activity required before therapies can reach patients. Managing these requirements efficiently often determines whether programs stay on schedule.
Each handoff between departments creates an opportunity for delays if priorities, documentation, or timelines are misaligned.
Trial Start-Up Bottlenecks
Many timeline challenges emerge before the first patient is even enrolled.
Clinical trial startup activities often involve contracting, budgeting, site qualification, protocol review, ethics committee approvals, training, and regulatory submissions. The National Library of Medicine identified startup processes as a significant operational phase that can affect trial timelines and study performance.
When startup activities become fragmented or heavily manual, delays can cascade throughout the entire program. Improvements made during the earliest stages of development often produce measurable benefits later in the trial lifecycle.
Manufacturing Readiness and Tech Transfer
A therapy cannot generate value if manufacturing operations are not prepared to support commercialization.
Process validation, equipment qualification, technology transfer, batch documentation, facility readiness, and quality oversight require extensive coordination across multiple teams. Delays in any of these areas can affect launch timelines.
Recognizing this challenge, the FDA has increased focus on manufacturing preparedness and supply chain resilience, including initiatives like the PreCheck Pilot Program, designed to engage manufacturers earlier in the development process.
Cross-Functional Misalignment
Life sciences programs typically involve multiple stakeholders across R&D, clinical operations, regulatory affairs, manufacturing, quality, supply chain, and commercial teams.
When these groups operate in silos, decision-making slows. Data may need to be reconciled across multiple systems, approvals become delayed, and teams struggle to maintain visibility into project status.
This is one reason many companies are investing in connected facilities, digital processes, and functional service partnerships that improve coordination across the product lifecycle.
Increasing Speed to Market Requires the Right Support
The ability to increase speed to market affects patient access, product value, resource utilization, and future innovation efforts. While scientific breakthroughs drive new opportunities, execution determines how quickly those breakthroughs reach the people who need them.
If your organization is looking for practical ways to increase speed to market, Insight Global can help you build the talent, processes, and operational support required to move programs forward and deliver results faster. Connect with us to learn more.
Find Life Sciences Solutions
Questions? Call us toll-free: 855-485-8853
